TrialThe Lancet. Child & adolescent health2022

Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.

Wendy Landier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.